Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 10/20 | 0.49 |
| ▸ | NPC1 | O15118 | 9/20 | 0.49 |
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | ECE1 | P42892 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3570499 | 0.90 | RAB9A (0.51) | RAB9ANPC1MAPTATMSMN1; SMN2 | |
| SCHEMBL3574726 | 0.89 | RAB9A (0.50) | RAB9ANPC1MAPTATMNAMPT | |
| SCHEMBL3577108 | 0.87 | RAB9A (0.50) | RAB9ANPC1MAPTATMSMN1; SMN2 | |
| SCHEMBL15361982 | 0.86 | RAB9A (0.52) | RAB9ANPC1MAPTATMNAMPT | |
| Hydrochloric Acid SCHEMBL3573666 | 0.85 | RAB9A (0.52) | RAB9ANPC1MAPTATMNAMPT | |
| SCHEMBL3568692 | 0.83 | RAB9A (0.49) | RAB9ANPC1MAPTATMSMN1; SMN2 | |
| SCHEMBL3573887 | 0.83 | RAB9A (0.49) | RAB9ANPC1MAPTATMSMN1; SMN2 | |
| SCHEMBL3153127 | 0.82 | RAB9A (0.60) | RAB9ANPC1MAPTATMSMN1; SMN2 | |
| SCHEMBL2815154 | 0.81 | RAB9A (0.55) | RAB9ANPC1MAPTATMNAMPT | |
| SCHEMBL2811019 | 0.79 | RAB9A (0.55) | RAB9ANPC1MAPTATMNAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735432-B2 | N-(Heteroaryl)-1-heteroarylalky1-1H-indole-2-carboxamide derivatives, preparation and therapeutic use thereof | SANOFI (FR) | 2014-05-27 | — | — | US | disclosed |
| EP-1910335-B1 | N-(HETEROARYL)-1-HETEROARYLALKYL-1H-INDOLE-2-CARBOXAMIDE DERIVATIVES, PREPARATION AND USE THEREOF | SANOFI SA (FR) | 2013-11-06 | — | — | EP | disclosed |
| US-20130046095-A1 | N-(Heteroaryl)-1-heteroarylalkyl-1H-indole-2-carboxamide derivatives, preparation and therapeutic use thereof | DUBOIS LAURENT (FR) | 2013-02-21 | — | — | US | disclosed |
| US-8318775-B2 | N-(heteroaryl)-1-heteroarylalkyl-1H-indole-2-carboxamide derivatives, preparation and therapeutic use thereof | SANOFI (FR) | 2012-11-27 | — | — | US | disclosed |
| US-20100222368-A1 | N-(Heteroaryl)-1-heteroarylalkyl-1H-indole-2-carboxamide derivatives, preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2010-09-02 | — | — | US | disclosed |
| US-7745467-B2 | N-(heteroaryl)-1-heteroarylalkyl-1H-indole-2-carboxamide derivatives, preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2010-06-29 | — | — | US | disclosed |
| US-20080146646-A1 | N-(Heteroaryl)-1-heteroarylalkyl-1H-indole-2-carboxamide derivatives, preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222368-A1 | N-(Heteroaryl)-1-heteroarylalkyl-1H-indole-2-carboxamide derivatives, preparation and therapeutic use thereof | IDO1, IDO2, CNR2 | RAB9A 2329/4885NPC1 230/4885MAPT 3396/4885 |
| US-20130046095-A1 | N-(Heteroaryl)-1-heteroarylalkyl-1H-indole-2-carboxamide derivatives, preparation and therapeutic use thereof | IDO1, IDO2, CNR2 | RAB9A 2329/4885NPC1 230/4885MAPT 3396/4885 |
| US-20080146646-A1 | N-(Heteroaryl)-1-heteroarylalkyl-1H-indole-2-carboxamide derivatives, preparation and therapeutic use thereof | IDO1, IDO2, CNR2 | RAB9A 2329/4885NPC1 230/4885MAPT 3396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.